GUERF(GUERF)
GUERF
8/28/26
Guerbet (GUERF)
Friday
8:02 AM
ThesisConcerns over reimbursement pressures and regulatory hurdles are overshadowing potential growth from new product launches.
Revenue Outlook
What Moves the Stock
- 01Regulatory approvals for new imaging agents
- 02Market share changes in the contrast agent segment
- 03Partnerships or collaborations with healthcare providers
- 04Emerging trends in medical imaging technology
- 05Contrast agents - 70%
- 06Medical imaging solutions - 20%
- 07Other healthcare products - 10%
- 08Advancements in medical imaging technology
FY2024 Snapshot
- Revenue
- $841M
- Rev. Growth
- +5.7%
- Gross Margin
- 26.3%
- Op. Margin
- 5.1%
- Net Margin
- 1.9%
- Net Income
- $16M
- NI Growth
- -32.6%
- EPS
- $1.28
GUERF Chart
No chart data
My Notes
- "Management noted, 'While we are excited about our upcoming products, we must navigate a challenging reimbursement landscape.'"
- Moat: Guerbet's competitive advantage lies in its proprietary formulations and established relationships with healthcare providers…
- value - Investors may be drawn to Guerbet due to its low valuation metrics (Price/Sales of 0.2x) and potential for recovery…
- The company's financing costs may increase with rising interest rates, impacting profitability.
- Watch on earnings: Revenue growth rate in the contrast agent segment, Operating cash flow trends, Debt/Equity ratio.
One Sentence Summary:
Guerbet: the story is balanced — regulatory approvals for new imaging agents.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.